Detecting EGFR T790M Mutations From Circulating Tumor Cells

The purpose of this research study is to determine if the EGFR mutation can be detected in CTCs. CTCs are cancer cells that are shed from solid tumors and float freely in the bloodstream. A device called the CTC-chip has been developed to find CTCs in the blood of patients with cancer. This is an experimental device. Using this device, the investigators will test participants' blood to try and find CTCs with the EGFR mutation and compare them with the results from the biopsy your doctor has recommended. The long-term goal of this research is to develop a way to test for the EGFR mutation that is less invasive than a tumor biopsy.

Study Overview

• Status: Completed
• Conditions: Non Small Cell Lung Cancer
• Intervention / Treatment: Device: Circulating tumor cell chip

Detailed Description

In order to participate in this study you need to have a diagnosis of NSCLC that has spread or is unable to be surgically removed. In addition, your cancer must have an EGFR mutation and you must have a scheduled (or recently performed) biopsy to check on the presence of any other mutations related to targeted drug resistance.

After you sign consent to participate in this study we will draw a blood sample (three tubes of blood). This is about 6 teaspoons of blood.

The number of CTCs in your blood will not be reported to you since it is not known if this number has any meaning or if it impacts your medical care in any way. These results will not become part of your medical record. They will be kept in a separate, secure location.

We will collect information from your medical records and store it in a research record that we create about you. The study team will use this information to compare details about your medical history with the results of the experiments done on your blood.

Genetic material (DNA) will be removed from the CTCs found in your blood. This genetic material will be stored at the Massachusetts General Hospital and studied along with samples from other participants on this research study. Your samples will not be labeled with your name or any information that identifies you. Your samples will have a study-specific code number on them. The code linking your name to the sample will be kept in a secure location, available only to the investigators of the study and select study team members.

After the blood draw we will follow your status every 6 months by reviewing your medical records.

• Study Type: Observational
• Enrollment (Anticipated): 40

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Dana-Farber Cancer Institute
    • Boston, Massachusetts, United States, 02115
      • Massachusetts General Hospital
  • New York
    • New York, New York, United States, 10065
      • Memorial Sloan Kettering Cancer Center
  • Texas
    • Houston, Texas, United States, 77030
      • MD Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Receiving treatment for NSCLC at one of the participating cancer centers

Description

Inclusion Criteria:

• Histologically confirmed NSCLC that is metastatic or unresectable
• Have agreed to undergo a clinically recommended invasive repeat tumor itssue biopsy

Exclusion Criteria:

-

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
NSCLC; Subjects with advanced NSCLC, will undergo blood draw	Device: Circulating tumor cell chip; three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip; Other Names: Herringbone circulating tumor cell chip, herringbone CTC chip, HBCTC chip

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients with detectable EGFR mutations in their CTCs	Calculate the number of patients in the study population with detectable EGFR mutations in the CTCs in order to demonstrate the feasibility of testing for EGFR mutations from captured CTCs	2 years
Number of patients with CTC-derived EGFR genotyping matching their tumor-derived EGFR genotyping	Determine the concordance of EGFR genotyping from CTCs compared to tumor tissue	2 yearss

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients with EGFR gentoype results detectable from plasma cfDNA	Explore the feasibility of EGFR genotyping from plasma circulating free DNA (cfDNA)	2 years

Collaborators and Investigators

• Sponsor: Massachusetts General Hospital
• Collaborators: M.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana-Farber Cancer Institute

Study record dates

Study Major Dates

• Study Start: November 1, 2012
• Primary Completion (ACTUAL): September 1, 2016
• Study Completion (ACTUAL): September 1, 2016

Study Registration Dates

• First Submitted: November 4, 2012
• First Submitted That Met QC Criteria: November 25, 2012
• First Posted (ESTIMATE): November 28, 2012

Study Record Updates

• Last Update Posted (ESTIMATE): September 26, 2016
• Last Update Submitted That Met QC Criteria: September 23, 2016
• Last Verified: September 1, 2016

More Information

Terms related to this study

• Keywords: Advanced; EGFR mutation
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Neoplastic Processes; Neoplasm Metastasis; Neoplastic Cells, Circulating; Antineoplastic Agents; Iproplatin
• Other Study ID Numbers: 12-353